Linksbridge SPC

Image of an Incepta R&D facility.

WHO prequalification of Incepta Pharmaceuticals's generic version of the Sayana Press, a 3-month injectable contraceptive that can be self-administered, potentially gives millions more people access to a discreet, convenient, affordable option: linksbridge-8615684.hs-sites-na2.com/this-weeks-r...

Stakeholder meeting report: Chikungunya virus – recent outbreaks, vaccine development and the way forward The International Vaccine Institute and Gorgas Institute (Gorgas Memorial Institute for Health Studies) organized the first Chikungunya Global Meeting…

🚨 New publication alert!

At the first Chikungunya Global Meeting in Panama City, stakeholders reviewed insights from recent outbreaks and discussed research priorities. Linksbridge's Katelyn Dinkel presented our chikungunya vaccine demand forecasting work and is an author of the meeting report:

Reports identify weakness in global pipeline for new antibiotics, diagnostics

The WHO says the pipeline for new antibiotics faces a "dual crisis" of scarcity and lack of innovation and that low-resource settings need simpler and faster diagnostic tests.

www.cidrap.umn.edu/a...

Linksbridge Pharma: this week's highlights Ghana ups wager on local vaccines Ghanaian President John Dramani Mahama has committed $50 million to “fast-track” the country’s vaccine production. The funds will support Ghana’s National Vaccine Ins...

This week's issue has something for everyone: news about African vaccine manufacturing, updates on lenacapavir access, a look at MNCs' retreat from U.K. investments, results from a malaria vaccine clinical trial, and more.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights PEPFAR recommits to lenacapavir access After threats to dismantle PEPFAR cast doubt over an access deal for Gilead’s lenacapavir PrEP drug, the U.S.

A Phase 3 trial has shown that the Zabdeno/Mvabea Ebola vaccine regimen induced antibody responses in pregnant women and their infants.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Bedaquiline price cut pushes BPaLM under $300 Indian generics manufacturer Lupin has slashed the price of its tuberculosis drug bedaquiline by 30%, bringing the cost of a six-month course of the WHO-r...

This week's issue spotlights an impact analysis from our friends at MedAccess. The numbers are impressive: the nonprofit has reached 559 million people to date with vaccines, diagnostics and other health technologies supported by its agreements. www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights ‘Danger to health’: U.S.

In an about-face, the U.S. FDA has suspended Valneva’s chikungunya vaccine just weeks after lifting an earlier pause on use of the jab. More on this development and other pharma news important to global health in this week's issue.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Phase 1 findings fuel nOPV trials in children Results from a first-in-human study of novel type 1 and type 3 oral poliovirus vaccines (nOPV1 and nOPV3, respectively) in adults are bolstering the case ...

Efforts to advance next-generation oral vaccines against polio type 1 and 3 got a boost this week with new Phase 1 trial data showing that the candidates performed similarly to their monovalent Sabin-strain comparators.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights WHO PQs first spatial emanators for vector control As insecticide resistance grows and shifting mosquito behavior threatens the effectiveness of long-standing vector control tools, WHO has prequalifie...

WHO has endorsed a new lifesaving tool in the fight against malaria. Two spatial emanator products from SC Johnson notched WHO prequalification this week, ushering in a new class of intervention for malaria vector control.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights BARDA abandons mRNA vaccine R&D In a move decried by public health leaders as shortsighted and baseless, the U.S.

BARDA is culling funding for mRNA vaccine R&D—a move public health officials say will hobble the country's capacity to combat the next pandemic. More on this development and other pharma news important to global health in this week's highlights.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Non-invasive test detects infant meningitis An ultrasound-based test detected meningitis in neonates and infants with 94% accuracy, offering a potential non-invasive alternative to the traditional lumbar puncture diagnostic method, according to results of an international study published last week i

Lumbar puncture—an invasive technique with significant practical limitations—is the gold standard for diagnosing meningitis. Now, a non-invasive test may be on the horizon.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Funding cuts loom over AIDS Society Conference Against the backdrop of a collapsed U.S.

The early days of this week's International AIDS Society Conference on HIV Science (IAS 2025) highlighted potentially epidemic-ending interventions and an urgent need for a reimagined funding landscape.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights First malaria drug approved for newborns Novartis’ infant-friendly version of antimalarial Coartem has scored the first approval for a malaria drug for babies weighing less than 4.5 kilograms.

Efforts to boost access to lifesaving medicines made strides this week: Novartis pledged to offer its infant-friendly antimalarial at a not-for-profit basis in malaria-endemic areas and Gilead finalized a deal with the Global Fund for its HIV PrEP drug.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Gavi nabs price pledges from GSK, Merck, SII Manufacturer commitments at Gavi’s replenishment summit last week could save Gavi-supported programs up to $200 million by 2030, according to a press relea...

Gavi's recent replenishment summit scored big: vaccine makers made pledges that could unlock up to $200 million in savings for Gavi-supported programs. This week's issue unpacks these commitments and other pharma news important to global health.
www.linkedin.com/pulse/linksb...

A Gilead researcher holds up a vial in an image provided by Gilead's PR apparatus.

With US FDA approval of a twice-yearly shot that prevents HIV, global health actors are mobilizing to secure access. This week's issue reviews Gilead's promises and stakeholders' doubts: linksbridge-8615684.hs-sites.com/this-weeks-r...

Linksbridge Pharma: this week's highlights Merck’s single-dose dengue jab enters Phase 3 Merck last week launched a Phase 3 trial of V181, its live attenuated quadrivalent vaccine candidate to prevent dengue disease regardless of prior dengue ...

This week's issue covers a flurry of vaccine development news. Among the highlights: Merck moved its dengue jab to Phase 3, GSK licensed its Shigella candidate to Bharat Biotech, and Micron Biomedical launched a trial of microarray-delivered rotavirus vaccine.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Tanzania plans local ARV production Amid a continuing crisis in global health funding, Tanzania has unveiled plans to manufacture HIV antiretrovirals (ARVs) and other essential medicines by bringing n...

Amid dwindling global health funding and tightening national budgets, Tanzania is making a strategic push toward pharmaceutical independence. This week's issue covers the country's plans to domestically manufacture HIV antiretrovirals and other essential medicines.

www.linkedin.com/pulse/linksb...

Amid significant funding cuts, global health stakeholders must find ways to do more with less.

That's one takeaway Linksbridge's KJ Zunigha heard in Geneva during the 78th World Health Assembly: www.linksbridge.com/resources/wh...

Linksbridge Pharma: this week's highlights U.S.

The search for an elusive HIV vaccine was dealt a major blow this week when the U.S. government notified the Consortia for HIV/AIDS Vaccine Development that it would pull the plug on a yearslong investment into the group's vaccine R&D efforts.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights GSK-licensed UTI antibiotic succeeds in Phase 3 GSK’s $66 million gamble on Spero Therapeutics’ tebipenem antibiotic appears to be paying off: the companies announced Wednesday that a Phase 3 trial ev...

In this week's issue, we explore funding for new and urgently needed gonorrhea treatments and the U.K.'s planned launch of a landmark vaccination campaign against the disease.
www.linkedin.com/pulse/linksb...

As they laid out Covid vaccine policy, the FDA chief & the top vaccine regulator contradicted their boss's stated views on measles jabs ("safe & highly effective," they said) while blaming falling immunization rates on ... other stuff. How much have they clarified?

pharma.linksbridge.com/news/34196

Join our partners at @taskforce.bsky.social for a walkthrough of CAS.tools -- a resource package for more effective, efficient, and equitable health campaigns.

Linksbridge Pharma: this week's highlights African firm scores sublicense for SD Bio’s diagnostic tech A newly launched Nigerian diagnostics venture has signed the first sublicensing agreement for a technology under WHO’s Health Technology Acc...

While pharma companies chase GLP-1 profits, sustainable access to affordable insulin remains out of reach for children and young people in LMICs. In this week's issue, we explore a new Access to Medicine Foundation report highlighting critical gaps in diabetes care.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights Announcing ‘radical’ departures, U.S.

The U.S. government’s role in the vaccine ecosystem grew even murkier over the past week.

Read about the current administration's puzzling—and concerning—moves in this week’s highlights.

www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights ‘Fridge-free’ Td vaccine enters Phase 1 Stablepharma has dosed the first participant in a Phase 1 trial of the “world’s first” fridge-free tetanus and diphtheria vaccine, according to a Monday press r...

This week’s issue highlights R&D advancements of a “fridge-free” reformulation of a WHO-prequalified tetanus and diphtheria vaccine developed using a technology that aims to address cold chain challenges, reduce costs, and improve health outcomes.
www.linkedin.com/pulse/linksb...

Linksbridge Pharma: this week's highlights TB drug news: price cuts, long-acting injectables R&D India’s Lupin has slashed the price of its tuberculosis drug pretomanid by 25%, a reduction the Stop TB Partnership’s Global Drug Facility (GDF) p...

This week's issue covers a smattering of tuberculosis product news. A generics manufacturer slashed the price of its TB drug pretomanid, an ultrasensitive point-of-care urine test won GHIT backing, and more.
www.linkedin.com/pulse/linksb...

Yesterday, we published a fourth edition of our emergency coverage of the impacts U.S. foreign aid cuts are having on health and nutrition programs around the world: linksbridge-8615684.hs-sites.com/taking-stock...

Linksbridge Pharma: this week's highlights Pandemic Agreement advances to World Health Assembly After more than three years of discussions, negotiators have finalized a proposal for a WHO Pandemic Agreement, per a WHO announcement on Wednesday...

A proposal for a WHO Pandemic Agreement is heading to the World Health Assembly after three years of negotiations. Notably missing from the list of governments that agreed on the treaty: the United States.

www.linkedin.com/pulse/linksb...

Providing an update on the Nigeria🇳🇬 country experience of using the Health Campaign Effectiveness Hub to identify opportunities for co-delivery, we hear from Zaiyanatu Abubakar Umar & Aline Benson @linksbridge.bsky.social working w the Health Campaign Effectiveness Coalition. #25NTDPMM

2024 Impact Report As a social purpose corporation (SPC), Linksbridge publishes an annual report reviewing our progress toward our impact goals.

In 2024, Linksbridge donated over $40,000 in awards to grantees through the Linksbridge Foundation.

Our 2024 Impact Report highlights how we made a difference to the world we're part of: www.linksbridge.com/impact-repor...